PharmiWeb Today Story
GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)
GSK's acquisition of efimosfermin represents a significant strategic move for GSK in the hepatology space. The promising Phase II data and unique properties of efimosfermin, coupled with the substantial unmet medical need in SLD, position this asset as a potential new standard of care. The acquisition strengthens GSK's pipeline and offers opportunities for both monotherapy and combination approaches, with a potential launch in 2029. This investment underscores GSK's commitment to developing precision interventions for fibrotic liver diseases.
Read More...
Articles
What Does a Pharmaceutical Account Manager Do?
04-Mar-2025
Top 10 Highest Paying Pharma Jobs in 2025
18-Feb-2025
The Impact of AI on Pharmaceutical Sales
13-Feb-2025
What Does a Medical Science Liaison Do?
18-Sep-2023
Featured Events
-
Next Generation Cancer Vaccine Development Summit…
07-Sep-2021 - 09-Sep-2021 -
Reuters Events: Pharma 2022
11-Oct-2022 - 13-Oct-2022 -
AI in Healthcare Summit Boston 2022
13-Oct-2022 - 14-Oct-2022 -
How to impact, influence & inspire
07-Feb-2023 - 21-Feb-2023 -
Reuters Events: Pharma USA 2023
28-Mar-2023 - 29-Mar-2023 -
Reuters Events: Pharma 2023
18-Apr-2023 - 20-Apr-2023
News
-
Heidelberg Pharma to Present Promising New Clinica…
14-May-2025 -
Leafbuyer Technologies, Inc. Announces Quarterly R…
14-May-2025 -
Bausch Health Announces 2025 Annual Meeting of Sha…
14-May-2025 -
Aytu BioPharma Reports Fiscal 2025 Third Quarter O…
14-May-2025 -
CV Sciences, Inc. Reports First Quarter 2025 Finan…
14-May-2025 -
Akero Therapeutics and HistoIndex Present New Anal…
14-May-2025
